| Methods |
2‐week single‐blind placebo run‐in; inclusion criteria= sitting DBP 95‐109 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
All patients: n=130; 102(79%) caucasian, 25(19%) black, 3(2%) oriental;
Cilazapril 2.5 mg: n=44(22 males,22 females); mean age=52.5(9.0) years; baseline sitting SBP=153.6(16.4) mm Hg, DBP=102.0(4.7) mm Hg;
Cilazapril 5 mg: n=42(31 males,11 females); mean age=50.4(9.1) years; baseline sitting SBP=154.8(15.1) mm Hg, DBP=101.0(4.3) mm Hg;
Placebo: n=44(29 males,15 females); mean age=53.6(8.5) years; baseline sitting SBP=157.5(15.8) mm Hg, DBP=101.1(3.8) mm Hg |
| Interventions |
Cilazapril 2.5 mg once daily;
Cilazapril 5 mg once daily;
Placebo |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
Peak sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP reported, endpoint SD not reported; baseline SBP SD reported, imputed baseline SBP SD for SBP SD of change, imputed overall trial mean DBP SD of change; BP data from Table 3, p. 608; Jadad score=3; funding source= Hoffman‐La Roche Ltd. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
